EGFR and cancer: They discovered that common driver mutations, including TP53 and EGFR, were consistent between paired primary and metastatic tumors, although the liver metastases demonstrated a similar mutational landscape than the BM samples when paired with the primary cancer, suggesting that actionable mutations identified from a single biopsy taken from the primary cancer may not represent in the mutations observed in the BM.